RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20
RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $19 to $20.
Read original at benzingaStocks · News reference
Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27
Details of the Proffered Paper Oral PresentationTitle: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)Presenter: Sumanta Pal, M.D., FASCO, Professor and
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 1:13 PM
- Checked
- Jul 17, 2026, 1:13 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Maintains Outperform on Xencor, Raises Price Target to $30
Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $26 to $30.
Read original at benzingaCantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44
Cantor Fitzgerald analyst Steve Seedhouse maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $43 to $44.
Read original at benzingaXencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.79) by 62.82 percent. This is a 29.27 percent increase over losses of $(0.41) per share from the same
Read original at benzinga